Rivastigmine Tartrate
Rivastigmine Tartrate (CAS: 129101-54-8) is the hydrogen tartrate, or L-tartrate, salt of rivastigmine, supplied as a white to off-white crystalline solid. It is a dual, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase, enzymes that metabolize acetylcholine. Its principal commercial role is as an active pharmaceutical ingredient for dementia medicines, including products used in Alzheimer’s disease and Parkinson’s disease dementia. Reported formulation formats include oral capsules, oral solutions, and transdermal patches. The material is also offered for laboratory and reference applications alongside its pharmaceutical use.
• Used as an active pharmaceutical ingredient in medicines for dementia associated with Alzheimer’s disease and Parkinson’s disease; its cholinesterase inhibition supports increased acetylcholine levels in the brain.
• Pharmaceutical manufacturers formulate the tartrate salt into oral capsules, oral solutions, and transdermal patches, with the salt form reported to support stability and solubility for formulation.
• Supplied in research and reference-standard grades for laboratory studies, analytical testing, and pharmaceutical quality-control work; these materials are not interchangeable with approved drug product.
Product Name: Rivastigmine Tartrate
For global customers, we provide complete technical documentation to support product evaluation, regulatory compliance and safe handling during transportation and application.